Circulating tumor DNA: current implementation issues and future challenges for clinical utility

What is it about?

In recent years, a method called liquid biopsy, mainly analyzing circulating tumor DNA (ctDNA), has become popular for non-invasively detecting cancer, including finding it early, monitoring its return, and checking how well treatments are working. New technologies in sequencing and AI have made these tests more accurate, especially for solid cancers. However, using these tests to help doctors decide on treatments can be complicated. We're now looking at how to best use ctDNA in areas like early cancer detection and personalized treatments, and we're also focusing on more research and clinical studies to support these uses in the future.

Featured Image